FMP
NASDAQ
71.47 USD
-1.48 (-2.07%)
Dr. Samarth Kulkarni Ph.D.
Healthcare
Biotechnology
https://www.crisprtx.com
NASDAQ
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell d...
0001674416
CH0334081137
H17182108
Baarerstrasse 14
41 41 561 32 77
CH
407
Oct 19, 2016
0001674416
NASDAQ
Biotechnology
Healthcare
H17182108
CH0334081137
CH
71.47
1.78
2.15M
6.02B
-
37.55-91.1
-32.48
-
-
-
-
-36.84
-
https://www.crisprtx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.